OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Very good news and the " representing one of the most effective therapies reported
in the field to date." part interests me. I expect more news on the lentivector programme over the next couple of mths and coupled with a statement on Trovax could really boost the sp. Takeover possibility has not been erased either, so i am still predicting this as share of the year..and next!

i have had oxb for about 3 years so far and have not seen any bad news for it. they have several good products in the pipeline and keep on making steady progress. Trovax is coming towards its final stages of development soon (ish) and it will be nice to see how this effects the company.

chart is looking good; any experts to say what the next level of resistance is?

I would be very wary of applying any meaningful form of TA to this share. Historically 45p appears the next medium-term resistance level but I have found that any form of TA that spans more than 2yrs worth of data is highly suspect.

1 share sold at 2.00pm today. What`s the logic there ?

maybe it's a golden share :)

Seems there is every chance of reaching 40p to-day (given the buys v sells ratio)
but for some reason SP is stuck and resisting - any views ??

More Super news for OXB and knowing that there is always a delayed reaction to news boosting the sp, should easily pass through 40p this week. This news means that OXB has an excellent portfolio of drugs/treatments/drug delivery systems that puts it at the forefront of the new age Gene technolgy that will see future cures of many diseases. "LONDON (AFX) - Gene therapy company Oxford Biomedica PLC said the first stage of its Phase II trials for the pancreatic cancer treatment MetXia has been successfully completed, with 'encouraging' results, and that it is now recruiting patients for the second stage of trials.

MetXia comprises a highly engineered retrovirus that delivers the P450 gene, which acts like the naturally occurring enzyme P450 in activating the chemotherapy drug cyclosphosphamide (CPA) in the body, to tumour cells.

MetXia and CPA are being evaluated for use by patients undergoing palliative surgery for pancreatic cancer.

Oxford BioMedica chief executive Alan Kingsman said: 'It is very encouraging that MetXia has achieved its endpoints of safety and gene transfer with this novel route of delivery.'

'We look forward to evaluating clinical benefit in the next stage of the trial. There is a clear unmet need for effective therapies for pancreatic cancer, which MetXia has the potential to address. '

FT.com
Oxford Biomedica rose 2.2 per cent to 35p amid speculation the gene therapy group was close to agreeing a deal with Pfizer to develop TroVax, a colon cancer treatment. Oxford, which already has a licencing agreement with Pfizer for its lentivirus-based gene technology, could announce a deal in the next few weeks.

Thank's Barry. They kept that quiet, no announcements yet. This, I believe is the most significant piece of news to come so far! and really endorses Trovax. Watch these, they will rocket before long, patience is about to be rewarded.

Why is the share price slipping when the buys outnumber sells by more than 2:1.?

If that persists then the mms will have to raise the price soon, expect some news very soon on Trovax which should shake things up. There's also been speculation in the past about a takeover approach and if OXB are to be taken over, it would have to be a very good deal as the Kingsmans own the majority of shares and they're going to want the co's technology taken all the way by the likes of Pfizer, they're getting on so I wouldn't rule out a deal that would reward them handsomely whilst keeping them on as consultants to see through the raft of products to commercialisation. As time moves on and no bad news is released, the shares become more valuable, with the breakthrough announcement ever closer!

Could we be close?

Fingers crossed...

From the Mail on Sunday:

"Rather more immediate is likely to be the deal between OXFORD BIOMEDICA and American drug giant PFIZER. The British Biotechnology Company group has long been expected to announce a deal for PFIZER to develop and market TroVax,its treatment for colon cancer. The deal is likely to be announced tomorrow and it should give Oxford shares a powerful lift as Pfizer's muscle could help turn TroVax into a blockbuster drug."

Cheers, Madison

The market is beginning to believe that time is nigh - keep your bowels open this could be it.

I'm sure this week will see it through the 40p, whether a Trovax deal will be announced I'm not sure, it may be early days for that but any news on Trovax is going to be very good for the sp

The Time could really be good now for OXB. The most attractive investment opportunities often arise in sectors which have done little to set investors' pulses racing over recent years. Investors' attitudes to them can become dismissive, so they spend little time examining them closely. Spotting when things are about to turn around is the key. OXB has the potential of several Blockbuster drugs and the years of research and trials are starting to pay off with some very exciting results (see co. website and news releases for more info)

On top of that is the cyclical nature of the Biotech sector and from the graphs of OXB and the sector, the chances of a Biotech sector rally are high. According to Framlington this area appears to be priced about 35% below its historical average, hopefully giving plenty of scope for prices to increase. In addition, as the industry has begun to mature there is a large pipeline of new products coming through.

And on top of that, there are big noises from large predators who are eagre to get their hands on the Bio Blockbusters of the future:

From Times Online 1/8/05: http://business.timesonline.co.uk/section/0,,9068,00.html

JAPANS biggest pharmaceutical group has amassed a 1.5 trillion yen (8 billion) war chest and is planning an acquisition spree as it vies for global competitiveness with rivals such as GlaxoSmithKline and Pfizer.
Although a drugs titan in Japan, Takeda ranks only 14th in the world a position that the groups president is eager to improve. In an exclusive interview with The Times, Yasuchika Hasegawa described a desire to put his group on the global map by using its cash to create a pipeline of blockbuster drugs.

With all these factors mounting, the outlook for OXB is looking very interesting.

We now see that Man Financial are holding 6% - could be both interesting and significant

Are we on the verge of a major announcement??..

FT.com

Oxford BioMedica has also recently seen significant changes in its share register. The increasing share stake of Credit Agricole Cheuvreux International (CACI) is worth noting. On April 22 Oxford announced that CACI’s shareholding was 8 per cent and on June 30 it reported that the stake had risen to 9.82 per cent. By July 6 it was 10.06 per cent.

Oxford BioMedica said on June 6 that it had signed a licence agreement for its LentiVector gene delivery technology to be used by major pharmaceutical firm Pfizer.

On August 1, Oxford BioMedica reported it had successfully completed the first stage of its phase 2 trial for the use of MetXia, the company’s “gene targeted prodrug activation product” in pancreatic cancer.

The company has a number of other products in research and development, including TroVax for colorectal cancer, ProSavin for Parkinson’s disease, MoNuDin for motor neurone disease and Innurex for spinal cord injury.